Seminars in Hematology
Volume 46, Issue 2 , Pages 110-117 , April 2009

Staging Systems and Prognostic Factors as a Guide to Therapeutic Decisions in Multiple Myeloma

  • Marie-Christine Kyrtsonis

      Affiliations

    • First Department of Propedeutic Internal Medicine and Hematology Department, National and Kapodistrian University of Athens Medical School, Laikon General Hospital, Athens, Greece
    • Corresponding Author InformationAddress correspondence to Marie-Christine Kyrtsonis, MD, First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens' School of Medicine, Laikon University Hospital, Agiou Thoma 17, Athens 11727, Greece
    • ,
  • Dimitrios Maltezas

      Affiliations

    • First Department of Propedeutic Internal Medicine and Hematology Department, National and Kapodistrian University of Athens Medical School, Laikon General Hospital, Athens, Greece
    • ,
  • Tatiana Tzenou

      Affiliations

    • First Department of Propedeutic Internal Medicine and Hematology Department, National and Kapodistrian University of Athens Medical School, Laikon General Hospital, Athens, Greece
    • ,
  • Efstathios Koulieris

      Affiliations

    • First Department of Propedeutic Internal Medicine and Hematology Department, National and Kapodistrian University of Athens Medical School, Laikon General Hospital, Athens, Greece
    • ,
  • Arthur R. Bradwell

      Affiliations

    • Department of Immunology, University of Birmingham, Birmingham, UK

References 

  1. Blade J, Munoz M, Fontanillas M, et al. Treatment of multiple myeloma in elderly people: long term results in 178 patients. Age Ageing. 1996;25:357–361
  2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33
  3. Rajkumar SV. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol. 2007;20:665–680
  4. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;13(Suppl 2):56–63
  5. Chombart B, Lemoussu LG, Eschard JP, et al. Factors useful for predicting survival of myeloma patients in everyday practice (A 10-year study of 148 patients older than 55 years). Joint Bone Spine. 2005;72:544–549
  6. Durie BG, Salmon SE. A clinical staging system for multiple myeloma (Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival). Cancer. 1975;36:842–854
  7. Cavo M, Galieni P, Zuffa E, Baccarani M, Gobbi M, Tura S. Prognostic variables and clinical staging in multiple myeloma. Blood. 1989;74:1774–1780
  8. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;20:3412–342023
  9. Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108:2013–2019
  10. Eleuterakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations and prognostic significance. Leuk Lymphoma. 2007;48:337–341
  11. Ho AD, Fiehn W, Hunstein W. Intracellular lactic dehydrogenase and phosphohexoseisomerase activity in leukemia and malignant lymphoma. Br J Hematol. 1982;50:637–645
  12. Vezzoni MA, Lucchini R, Giardini R, Raineri M, Murone M, Vezzoni P. Lactate dehydrogenase levels in cellular extracts of human malignant lymphomas. Tumori. 1983;31:279–28269:
  13. Simonsson B, Brenning G, Källander C, Ahre A. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma. Eur J Clin Invest. 1987;17:336–339
  14. Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med. 1989;1:110;521-5
  15. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;15:931–935115:
  16. Simonsson B, Kallander CF, Brenning G, Killander A, Gronowitz JS, Bergstrom R. Biochemical markers in multiple myeloma: a multivariate analysis. J Haematol. 1988;69:47–53
  17. Blade J, Rozman C, Cervantes F, Reverter JC, Montserrat E. A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol. 1989;72:507–511
  18. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33
  19. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441–450
  20. Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma, Blood. 1996;88:1780–1787
  21. Cassuto JP, Krebs BP, Joyner MV, Viot G, Dujardin P, Audoly P, et al. β2-Microglobulin in lymphoproliferative disorders with special reference to gammapathies. Pathol Biol (Paris). 1978;26:345–347
  22. Garewal H, Durie BG, Kyle RA, Finley P, Bower B, Serokman R. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol. 1984;2:51–57
  23. Bettini R, Redaelli S, Maino C, et al. Prognostic value of serum beta-2 microglobulin in multiple myeloma. Recent Prog Med. 2005;96:81–85
  24. Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood. 1995;85:765–771
  25. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, Leukemia. 2009;23:215-24.
  26. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 2007;137:240–243
  27. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the International Staging System. Leukemia. 2008;22:1933–1937
  28. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, et al. Appraisal of immunoglobulin free light chain as a marker of response, Blood. 2008;111:4908–4915
  29. Hassoun H, Reich L, Klimek V, Dhodapkar M, Cohen A, Kewalramani T, et al. The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2005;106:3481
  30. Mösbauer U, Ayuk F, Schieder H, Lioznov M, Zander A, Kröger N. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica. 2007;92:275–276
  31. Kumar S, Dispenzieri A, Larson D, Colby C, Kyle R, Gertz M, et al. Normalization of the serum free light chain (flc) ratio is associated with superior overall survival among myeloma patients achieving immunofixation negative state: results support incorporation of serum flc ratio in stringent cr definition [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:1692
  32. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827–832
  33. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18:886–895
  34. Bataille R, Harouseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657–1664
  35. Mitsiades N, Mitsiades C, Munshi N, Richardson P, Anderson K. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42:1564–1573
  36. Kyrtsonis M-C, Dedoussis GVZ, Zervas C, et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol. 1996;93:398–400
  37. Pulkki K, Pelliniemi TT, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma (Finnish Leukaemia Group). Br J Haematol. 1996;92:370–374
  38. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991;77:2794–2795
  39. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000;95:388–392
  40. Ribas C, Colleoni GW, Silva MR, Carregoza MJ, Bordin JO. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol. 2004;73:311–317
  41. Kyrtsonis M-C, Vassilakopoulos TP, Siakantaris MP, et al. Serum syndecan-1, basic fibroblast growth factor (bFGF), and osteoprotegerin (OPG) in myeloma (MM) patients. Eur J Haematol. 2004;72:252–258
  42. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma, Br J Haematol. 2003;123:106–109
  43. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index, Blood. 2003;102:1064–1069
  44. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382–3387
  45. Zervas K, Constantinou N, Karankantza M, Tsigalidou-Balla V. Anaplastic myeloma. Leuk Lymphoma. 1995;16:515–519
  46. Trendle MC, Leong T, Kyle RA, Katzmann JA, Oken MM, Kay NE, et al. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group Treatment Trial E9486. Am J Hematol. 1999;61:232–237
  47. Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki K, Niniraki M, Stathopoulos E. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol. 2004;27:8–13
  48. Gastinne T, Leleu X, Duhamel A, et al. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol. 2007;79:297–304
  49. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia. 1994;8:1280–1284
  50. Rajkumar SV, Palumbo A. Management of newly diagnosed myeloma. Hematol Oncol Clin North Am. 2007;21:1141–1156
  51. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996;94:217–227
  52. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520–1529
  53. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579–1583
  54. Drach J, Ackermann J, Fritz E, et al. Presence of a P53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–809
  55. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735–3741
  56. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947
  57. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood. 2003;101:4998–5006
  58. Decaux O, Lodé L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26:4798–4805
  59. Blade J, Rosinol L, Cibeia MT. Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol. 2008;19:117–120
  60. Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539–1543
  61. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733–737
  62. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441–450
  63. Prognostic features in the third MRC myelomatosis trial (Medical Research Council's Working Party on Leukaemia in Adults). Br J Cancer. 1980;42:831–840
  64. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250–4256
  65. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–4575
  66. Facon T, Avet-Loiseau H, Guillerm G, et al. Intergroupe Francophone du Myelome Chromosome 13 abnormalities identified by FISH analysis and serum b2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566–1571
  67. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041–1047
  68. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–1617
  69. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229–2238
  70. Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804–812
  71. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323–341
  72. Kyle RA. Newer approaches to the management of multiple myeloma. Cancer. 1993;72(Suppl):3489–3494
  73. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–789
  74. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165–2172
  75. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2007;31:779–782
  76. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–157
  77. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007;21:164–168
  78. Kelly TW, Baz R, Hussein M, et al. Clinical significance of cyclin D1, fibroblast growth factor receptor-3 and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Hum Pathol. 2009;20:405–412
  79. San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008;26:2761–2766
  80. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32:910–917

PII: S0037-1963(09)00032-8

doi: 10.1053/j.seminhematol.2009.02.004

Seminars in Hematology
Volume 46, Issue 2 , Pages 110-117 , April 2009

Article Tools

* Image Usage & Resolution